SCHEMBL2949801

SCHEMBL2949801

O=C(O)c1c(F)cccc1S

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CES2 O00748 2/20 0.54
CES1 P23141 2/20 0.54
ALB P02768 1/20 0.50
MAPT P10636 1/20 0.45
HDAC8 Q9BY41 1/20 0.45
CA12 O43570 1/20 0.43
CA1 P00915 1/20 0.43
CA2 P00918 1/20 0.43
CA7 P43166 1/20 0.43
CA9 Q16790 1/20 0.43
CA14 Q9ULX7 1/20 0.43
TTR P02766 1/20 0.42
TDP1 Q9NUW8 2/20 0.42
LMNA P02545 1/20 0.41
ITGB2 P05107 1/20 0.40
ICAM1 P05362 1/20 0.40
ITGAL P20701 1/20 0.40
MEN1 O00255 1/20 0.40
KMT2A Q03164 1/20 0.40
NPC1 O15118 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL260553 0.84 CES2 (0.67) CES2CES1ALBCA12CA1
SCHEMBL23601109 0.84 MAPT (0.54) MAPTHDAC8CA12CA1CA2
Hydrochloric Acid SCHEMBL7968059 0.81 CES2 (0.64) CES2CES1ALBCA12CA1
SCHEMBL3117223 0.81 CES2 (0.64) CES2CES1ALBCA12CA1
Formic Acid SCHEMBL28286083 0.80 CES2 (0.56) CES2CES1ALBCA12CA1
SCHEMBL17080273 0.76 CA12 (0.52) CES2CES1CA12CA1CA2
SCHEMBL30786267 0.76 GAA (0.52) CES2CES1TDP1ITGB2ICAM1
SCHEMBL1431399 0.76 MAPT (0.64) ALBMAPTHDAC8CA12CA1
SCHEMBL335939 0.76 ALB (0.63) CES2CES1ALBCA12CA1
SCHEMBL10745781 0.76 CA12 (0.70) MAPTHDAC8CA12CA1CA2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3859804-B1 SEMICONDUCTOR DEVICE HAVING QUANTUM DOTS CANON KK (JP) 2024-08-07 EP claimed
US-12245446-B2 Semiconductor device having quantum dots, display device, imaging system, and moving body CANON KABUSHIKI KAISHA (JP) 2025-03-04 US disclosed
EP-3859804-B1 SEMICONDUCTOR DEVICE HAVING QUANTUM DOTS CANON KK (JP) 2024-08-07 EP disclosed
CN-113285024-A Semiconductor device having quantum dots, display device, imaging system, and moving object 佳能株式会社 2021-08-20 CN disclosed
US-20210242416-A1 SEMICONDUCTOR DEVICE HAVING QUANTUM DOTS, DISPLAY DEVICE, IMAGING SYSTEM, AND MOVING BODY CANON KABUSHIKI KAISHA (JP) 2021-08-05 US disclosed
EP-3859804-A2 SEMICONDUCTOR DEVICE HAVING QUANTUM DOTS CANON KABUSHIKI KAISHA (JP) 2021-08-04 EP disclosed
WO-2021131845-A1 RADIATION-SENSITIVE RESIN COMPOSITION AND METHOD FOR FORMING PATTERN JSR株式会社 2021-07-01 WO disclosed
CN-110437153-A hepatitis B core protein allosteric modulators UNIV INDIANA RES & TECH CORP 2019-11-12 CN disclosed
CN-108347943-A HEPATITIS B CORE PROTEIN MODULATORS 组装生物科学股份有限公司 2018-07-31 CN disclosed
CN-106413402-A Hepatitis b core protein allosteric modulators 美国印第安纳大学研究和技术公司 2017-02-15 CN disclosed
US-7767665-B2 3-[6-(4-oxo-4H-1,3-benzothiazin-2-yl)-2-pyridyl]propionic acid, having an excellent apoptosis inhibitory and Macrophage migration inhibitory factor (MIF) binding effects, used for preventing and/or treating cancers, AIDS, cardiovascular, neurodegeneartive, bone, kidney and liver disoders TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2010-08-03 US disclosed
US-20090082343-A1 1,3-BENZOTHIAZINONE DERIVATIVES AND USE THEREOF TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2009-03-26 US disclosed
US-7399759-B2 1, 3-benzothiazinone derivatives and use thereof TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2008-07-15 US disclosed
US-20050032786-A1 1, 3-benzothiazinone derivatives and use thereof TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2005-02-10 US disclosed
EP-1424336-A1 1,3-BENZOTHIAZINONE DERIVATIVES AND USE THEREOF Takeda Chemical Industries, Ltd. (JP) 2004-06-02 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090082343-A1 1,3-BENZOTHIAZINONE DERIVATIVES AND USE THEREOF MIF, MORF4L1, FOXM1 CES2 4801/4885CES1 1955/4885ALB 3103/4885
US-20050032786-A1 1, 3-benzothiazinone derivatives and use thereof MIF, MORF4L1, FOXM1 CES2 4801/4885CES1 1955/4885ALB 3103/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.